Susquehanna International Group
LSB

Susquehanna International Group’s LakeShore Biopharma LSB Stock Holding History

Susquehanna International Group’s Portfolio LSB Stock Details LSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,167
Closed -$7.56K – 13236
2024
Q2 		$7.56K Buy
+1,167
New +$9.54K ﹤0.01% 11800
2023
Q3 		– Sell
-1,526
Closed -$21.1K – 13167
2023
Q2 		$21.1K Buy
+1,526
New +$22.6K ﹤0.01% 11625

Other funds holding LSB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's LSB Position: Q3 2024 in Review

Susquehanna International Group sold out of LakeShore Biopharma (LSB) in Q3 2024, closing a stake of 1,167 shares — an estimated $7.56K sold.

Susquehanna International Group first reported a position in LSB in Q2 2023 and held it in 2 quarters. The position peaked at $21.1K in Q2 2023. 7 funds tracked by Wall St. Rank hold LSB as of Q3 2024.

  • Susquehanna International Group reported no remaining LakeShore Biopharma position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 1,167 LakeShore Biopharma shares in Q3 2024, an estimated $7.56K.
  • Susquehanna International Group first reported a position in LakeShore Biopharma in Q2 2023 and held it in 2 quarters.
  • Susquehanna International Group's LakeShore Biopharma position peaked at $21.1K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.